Compare DAWN & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAWN | PRGO |
|---|---|---|
| Founded | 2018 | 1887 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.8M | 1.8B |
| IPO Year | 2021 | 1991 |
| Metric | DAWN | PRGO |
|---|---|---|
| Price | $8.46 | $13.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $26.56 | $22.50 |
| AVG Volume (30 Days) | 2.6M | ★ 3.8M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 8.83% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $133,672,000.00 | ★ $4,281,800,000.00 |
| Revenue This Year | $15.51 | N/A |
| Revenue Next Year | $49.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.11 | N/A |
| 52 Week Low | $5.64 | $12.17 |
| 52 Week High | $13.53 | $30.93 |
| Indicator | DAWN | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 33.23 |
| Support Level | $8.13 | $12.93 |
| Resistance Level | $8.67 | $13.63 |
| Average True Range (ATR) | 0.48 | 0.45 |
| MACD | -0.07 | 0.23 |
| Stochastic Oscillator | 25.82 | 17.69 |
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.